OncoMatch/Clinical Trials/NCT07217587
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Is NCT07217587 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Nipocalimab and Efgartigimod for myasthenia gravis.
Treatment: Nipocalimab · Efgartigimod — The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage MGFA CLASS II A/B, MGFA CLASS III A/B, MGFA CLASS IV A/B (MGFA)
MGFA clinical classification class II a/b, III a/b, or IV a/b at screening
Demographics
Prior therapy
Must have received:
Treatment with efgartigimod IV or subcutaneous (SC) for >=1 cycle, and the final cycle is consistent with product information
Cannot have received:
Had a thymectomy within 1 year prior to baseline, or thymectomy is planned during the study
Cannot have received:
Has received treatment for MG with an FcRn-targeting therapy
Cannot have received:
Exception: exception of efgartigimod
Is currently taking IgG monoclonal antibody therapeutics, or Fc-conjugated therapeutic agents, including factor or enzyme replacement, with the exception of efgartigimod
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Connecticut · Farmington, Connecticut
- SFM Clinical Research LLC · Boca Raton, Florida
- HSHS St. Elizabeth's Hospital · O'Fallon, Illinois
- Henry Ford Hospital · Detroit, Michigan
- Atrium Health Wake Forest Baptist · Winston-Salem, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07217587 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior , , disqualifies patients from enrollment.
What disease stage is eligible?
Stage MGFA CLASS II A/B or MGFA CLASS III A/B or MGFA CLASS IV A/B is required.
Is there an age limit?
Yes. Patients must be 74 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify